Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
13.58
+0.40 (3.03%)
At close: Dec 5, 2025, 4:00 PM EST
13.72
+0.14 (1.03%)
After-hours: Dec 5, 2025, 6:49 PM EST
Company Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia.
Benitec Biopharma Inc. is headquartered in Hayward, California.
Benitec Biopharma Inc.
| Country | United States |
| Founded | 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Jerel Banks |
Contact Details
Address: 3940 Trust Way Hayward, California 94545 United States | |
| Phone | 510 780 0819 |
| Website | benitec.com |
Stock Details
| Ticker Symbol | BNTC |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001552795 |
| CUSIP Number | 08205P100 |
| ISIN Number | US08205P2092 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jerel A. Banks M.D., Ph.D. | Executive Chairman and Chief Executive Officer |
| Megan Joan Boston B.Com., C.A. | Chief Financial Officer, Secretary and Director |
| Sophie Mukadam | Chief Operating Officer |
| Dr. Michael Graham | Head of Discovery and Founding Scientist |
| Dr. Claudia Kloth Ph.D. | Senior Vice President of Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2020 | 15-12B | Securities registration termination |
| Apr 16, 2020 | EFFECT | Notice of Effectiveness |
| Apr 16, 2020 | EFFECT | Notice of Effectiveness |
| Apr 15, 2020 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 15, 2020 | POS AM | Post-Effective amendments for registration statement |
| Apr 15, 2020 | POS AM | Post-Effective amendments for registration statement |
| Apr 15, 2020 | 6-K | Report of foreign issuer |
| Apr 14, 2020 | 25 | Filing |
| Apr 14, 2020 | 25-NSE | Filing |
| Apr 3, 2020 | 6-K | Report of foreign issuer |